The Vanguard Group has filed an amended Schedule 13G with the Securities and Exchange Commission (SEC), indicating a change in their holdings of bluebird bio, Inc. common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 10,474,007 shares of bluebird bio, which represents 5.40% of the company's class of common stock. This filing, made under Rule 13d-1(b), shows that The Vanguard Group has shared voting power over 87,543 shares and sole dispositive power over 10,330,825 shares, with an additional shared dispositive power over 143,182 shares. The filing indicates that The Vanguard Group's clients, including registered investment companies and other managed accounts, have the right to receive dividends or proceeds from the sale of these securities. The Vanguard Group, based in Pennsylvania, is a major investment adviser and reports no single client holding more than 5% of the interest in the reported securities.

The Vanguard Group has filed an amended Schedule 13G with the Securities and Exchange Commission (SEC), indicating a change in their holdings of bluebird bio, Inc. common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 10,474,007 shares of bluebird bio, which represents 5.40% of the company's class of common stock. This filing, made under Rule 13d-1(b), shows that The Vanguard Group has shared voting power over 87,543 shares and sole dispositive power over 10,330,825 shares, with an additional shared dispositive power over 143,182 shares. The filing indicates that The Vanguard Group's clients, including registered investment companies and other managed accounts, have the right to receive dividends or proceeds from the sale of these securities. The Vanguard Group, based in Pennsylvania, is a major investment adviser and reports no single client holding more than 5% of the interest in the reported securities.